Additional important developments in anti-HER2 directed therapy in gastric cancer now include antibody–drug conjugates such as trastuzumab deruxtecan in the advanced setting (52), and a potential role for XELOX-T (oxaliplatin, capecitabine, and trastuzumab) in locally advanced, resectable gastric cancer (53). The gene discussed is ERBB2; the disease is gastric cancer.